Amgen topped the Dow Jones Industrial Average with a 0.9% increase, continuing its strong year-to-date performance at 6.1%. The surge follows reports of a potential drug-pricing agreement between the Trump administration and the pharmaceutical industry, leading to a bullish atmosphere in healthcare stocks which contributed to gains in major U.S. equity indexes. Meanwhile, Amgen announced a $650 million expansion of its manufacturing network, expected to create around 750 jobs.